Clinical Trial

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

Study acronym: REMBRANDT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC daily on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-05; most recent amendment 2026-04-06.
Status change: Recruiting → Active, Not Recruiting 2026-04-06
Status change: Not Yet Recruiting → Recruiting 2024-11-12
Trial Details
NCT Number NCT06305559
Lead Sponsor NewAmsterdam Pharma
Conditions Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
Enrollment 300 participants
Start Date 2024-05-16
Primary Completion 2027-11 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-04-09